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patients after CPB, and 50% to 80% of them will not
have an identifiable surgical bleeding source.4
Fibrinolysis has been reported to be the cause of 25% to
45% of significant postbypass bleeding.5 Various
antifibrinolytic agents have been used to diminish post-
bypass bleeding. These include ε-aminocaproic acid,6
aprotinin,7,8 and, most recently, tranexamic acid
(TA).9,10 TA is a synthetic antifibrinolytic drug that acts
by attaching to the lysine-binding sites of plasmin and
plasminogen.11 Saturation of these sites displaces plas-
minogen from its fibrin surface, thereby inhibiting fib-
rinolysis. TA is 7 to 10 times more potent than ε-
aminocaproic acid and is far less expensive than
aprotinin.12 Intravenous TA administration has been
associated with an increased risk of thromboembolic
complications and early graft closure in coronary artery
bypass grafting (CABG).7,13 It has been demonstrated
that local antifibrinolytic activity provided by topical
application of TA is effective in preventing bleeding
after oral surgery in patients with hemophilia14 and in
D iffuse microvascular bleeding remains a commonproblem after myocardial revascularization with
cardiopulmonary bypass (CPB). The hemorrhagic
diathesis associated with CPB is widely known. It
results from a multifactorial coagulopathy in which the
predominant factors are thrombocytopenia, acquired
platelet dysfunction,1 loss of clotting factors,2 unneu-
tralized heparin, and increased fibrinolysis.3 Bleeding
necessitating re-exploration occurs in 2% to 7% of
Objectives: We sought to investigate the effect of topical application of
tranexamic acid into the pericardial cavity in reducing postoperative
blood loss in coronary artery surgery. Methods: A prospective, random-
ized, double-blind investigation with parallel groups was performed.
Forty consecutive patients undergoing primary coronary surgery were
randomly assigned to group 1 (tranexamic acid group) or group 2
(placebo group). Tranexamic acid (1 g in 100 mL of saline solution) or
placebo was poured into the pericardial cavity and over the mediastinal
tissues before sternal closure. The drainage of mediastinal blood was
measured hourly. Results: Chest tube drainage in the first 24 hours was
485 ± 166 mL in the tranexamic acid group and 641 ± 184 mL in the
placebo group (P = .01). Total postoperative blood loss was 573 ± 164 mL
and 739 ± 228 mL, respectively (P = .01). The use of banked donor blood
products was not significantly different between the two groups.
Tranexamic acid could not be detected in any of the blood samples
blindly collected from 24 patients to verify whether any systemic
absorption of the drug occurred. There were no deaths in either group.
None of the patients required reoperation for bleeding. Conclusions:
Topical application of tranexamic acid into the pericardial cavity after
cardiopulmonary bypass in patients undergoing primary coronary
bypass operations significantly reduces postoperative bleeding. Further
studies must be carried out to clarify whether a more pronounced effect
on both bleeding and blood products requirement might be seen in pro-
cedures with a higher risk of bleeding. (J Thorac Cardiovasc Surg
2000;119:575-80)
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TOPICAL USE OF TRANEXAMIC ACID IN CORONARY ARTERY BYPASS OPERATIONS: 
A DOUBLE-BLIND, PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED STUDY
patients who are being treated with anticoagulants.15
Topical TA has also been successfully used in epis-
taxis,12 bladder surgery,12 and gynecologic hemor-
rhages.16 This prospective, double-blind, randomized,
placebo-controlled study was designed to investigate
the effect of topical TA in reducing postoperative blood
loss in coronary artery surgery.
Methods
After institutional approval was obtained, all patients
scheduled for first-time elective CABG between March 1998
and November 1998 were eligible for enrollment.
Contraindications for enrollment included associated valve
surgery or any other combined procedure, administration of
platelet-activating drugs within 14 days of operation, bleed-
ing diathesis, history of thrombosis, creatinine levels of
greater than 160 mg/dL, heparin administration within 48
hours of operation, nonsteroidal anti-inflammatory medica-
tion within 3 days, or a known allergy to TA. During this 9-
month period, 214 patients underwent elective primary coro-
nary surgery at our institution. Forty patients met the
requirements for inclusion, and informed consent was
obtained from all of them. The study was carried out as a
prospective, randomized, double-blind investigation with par-
allel groups. The aim was to compare the hemostatic effect of
a 100-mL saline solution containing 1 g of TA with that of a
100-mL placebo saline solution. These two 100-mL solutions
were prepared in advance by the hospital pharmacy in identi-
cal bottles marked “A” and “B” and delivered to the operat-
ing theaters. TA (Tranex; Malesci Istituto Farmacobiologico,
Firenze, Italy), in ampules of 5 mL containing 100 mg of TA
per milliliter of saline solution without any other additives or
preservatives, was used for this purpose.
Randomization was carried out with random-number tables
by a research nurse attached to the Department of Cardiac
Surgery but not to the operating theaters. Sealed envelopes
were prepared and left in a box in the operating theater. On the
day of surgery, the theater nurse selected the next card from
the box, and this determined which solution was to be used.
Neither the surgeons, anesthetists, scrub nurses, nor the perfu-
sionists knew the composition of the solution administered.
Forty consecutive patients were randomly assigned to group 1
(TA group) or group 2 (placebo group). Only two cardiac sur-
geons were responsible for the surgical hemostasis. The anes-
thetic management and conduct of CPB were standardized.
All patients were premedicated with diazepam 0.1 to 0.15
mg/kg administered orally, morphine 0.1 to 0.15 mg/kg
administered intramuscularly, and scopolamine 0.01 mg/kg
administered intramuscularly. Anesthesia was induced with
fentanyl 3 to 5 µg/kg and thiopental 3 mg/kg and maintained
with boli of fentanyl 100 to 200 µg and midazolam 2.5 mg.
Arterial hypertension was controlled by isoflurane administra-
tion. Muscle paralysis was obtained with pancuronium bro-
mide 0.1 mg/kg. After endotracheal intubation, patients were
connected to a Servo Ventilator D (Siemens, Solna, Sweden).
Minute volume and fraction of inspired oxygen were adjusted
to achieve arterial PCO2 values between 30 and 45 mm Hg and
arterial PO2 values between 100 and 150 mm Hg. The extra-
corporeal circuit consisted of a hollow-fibber membrane oxy-
genator (Terumo Capiox E; Terumo Co, Tokyo, Japan).
Polyvinyl chloride tubing was used throughout the circuit,
except for the roller pump tubing, which was silicone rubber.
Before CPB was established, each patient received 3 mg/kg
bovine lung heparin; when the activated clotting time was
shorter than 400 seconds, additional doses of heparin were
administered. Heparin was reversed with protamine sulfate at
a 1.3:1 ratio. Normothermia at 37°C and isothermic intermit-
tent antegrade administration of blood potassium cardioplegic
solution were used in all patients. Left internal thoracic artery
grafts supplemented with saphenous vein grafts were routine-
ly used. The left pleural space was opened intentionally dur-
ing left internal thoracic artery harvesting. Before closure of
the median sternotomy, mediastinal and thoracic drains were
clamped, and 100 mL of saline solution (with or without 1000
mg of TA) at room temperature was poured into the pericar-
dial cavity and over the mediastinal tissues. The clamps on the
mediastinal and thoracic drains were released after closure of
the median sternotomy.
After the patient was transferred to the intensive care unit,
continuous low-grade suction (5 cm H2O) was applied, which
was supplemented with periodic milking of the drains.
Complete blood count, SMA-18 (Technicon Instruments
Corp, Tarrytown, NY), prothrombin time, partial thrombo-
plastin time, and platelet counts were measured before the
operation and when the patients arrived at the intensive care
unit. The drainage of mediastinal blood was measured hourly.
The mediastinal and thoracic drains were removed when the
total drainage was less than 240 mL over the previous 24
hours. Uniform transfusion criteria were adhered to in all
patients. Blood and blood components were administered
only when the hematocrit level fell to less than 0.24 or the
hemoglobin level fell to 7.5 g/L in the postoperative period.
Shed mediastinal blood was not transfused into any patient
during this study. The number of grafts, duration of CPB,
crossclamp time, incidence of reoperation for bleeding, and
amount of total chest tube drainage were recorded for all
patients. The plasma concentration of TA levels was assayed
by electron-capture gas chromatography 2 hours after
unclamping of the chest tubes to verify whether any systemic
absorption of this antifibrinolytic agent occurred after its top-
ical application into the pericardial cavity.15,17
Means and SDs were reported provided that no significant
deviations from normal distribution were observed graphical-
ly and with the Kolmogorov-Smirnov test. Differences
between the two groups of patients concerning hematologic
and coagulative parameters were analyzed by the 2-tailed,
unpaired, Student t test. Data about blood loss during the first
24 postoperative hours were analyzed by 2-way analysis of
variance (ANOVA) (TA vs placebo groups; time subdivided
into 3-hour intervals) for repeated measures. The comparison
of the blood loss during each 3-hour interval between the TA
and placebo groups was carried out by linear contrast, as well
as the comparison of the total amount of chest drainage after
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the first 24 postoperative hours. The difference in total post-
operative bleeding was analyzed by using the 2-tailed,
unpaired, Student t test because the chest tubes were removed
after a variable interval of time. Statistical analyses were
made by using Statistica for Windows software (Statsoft Inc,
Tulsa, Okla).
Results
The two groups were matched with regard to age,
sex, duration of operation, CPB time, and average
number of distal anastomoses (Table I). There was no
bias in the distribution of anesthesiologists and sur-
geons between the two groups. Preoperative and post-
operative hemoglobin concentrations, hematocrit lev-
els, platelet counts, prothrombin times, and partial
thromboplastin times were not significantly different
between the two groups (Tables II and III). No statisti-
cally significant differences were found in the dosage
of heparin or protamine administered during the opera-
tions. Chest tube drainage in the first 24 hours was 485
± 166 mL in the TA group and 641 ± 184 mL in the
placebo group (P = .01). This represents about a 25%
decrease in blood loss. Total postoperative chest tube
drainage was 573 ± 164 mL (range, 360-1020 mL) in
the TA group and 739 ± 228 mL (range, 365-1310 mL)
in the placebo group (P = .01), which corresponds to a
22% decrease in total bleeding. In addition, chest tube
drainage was compared between the two groups every
3 hours after operation (Fig 1). Blood loss from 0 to 3
hours was reduced by 36% in the TA group compared
with that in the placebo group (172 ± 81 vs 268 ± 95
mL, P < .001). In the following 3-hour intervals, the
amount of blood loss in the TA group was lower than
that found in the placebo group, but these differences
were not statistically significant. Intraoperative and
postoperative use of banked donor blood products was
not significantly different between the two groups.
Three (15%) patients in the TA group and 4 (20%)
patients in the placebo group required an average of 2.3
and 2.2 packed red blood cell units, respectively (1 unit
= approximately 360 mL). No fresh frozen plasma, cryo-
precipitate, or platelets were transfused in any group.
Blood samples for determination of TA levels were
blindly collected 2 hours after unclamping of the chest
tubes from 24 patients: 13 belonged to the TA group
and 11 to the placebo group. None of these patients had
detectable levels of TA. There were no deaths in either
group. None of the patients required reoperation for
bleeding. One patient in the placebo group had a peri-
operative myocardial infarction, as indicated by elec-
trocardiographic and echocardiographic changes and
plasma concentrations of cardiac enzymes.
Discussion
Various clinical studies have shown that intravenous
administration of TA is effective in decreasing postoper-
ative bleeding and transfusions in primary CABG, as
well as in reoperative cardiac surgery.9,10,18 TA is a syn-
thetic antifibrinolytic drug that acts by attaching to the
lysine-binding sites of plasmin and plasminogen.11
Saturation of these sites displaces plasminogen from the
fibrin surface, inhibiting fibrinolysis. Moreover, TA
inhibits plasmin-induced platelet activation, consequent-
ly preserving platelet function.19 In the effort to reduce
postoperative blood loss after CPB by using antifibri-
nolytic agents, the benefit must always be discussed in
reference to a potential increased risk of thromboembol-
ic complications. Indeed, cases of cerebral,20,21 pul-
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Table I. Patient demographics
Placebo 
TA group group P value
Age (y) 62 ± 7 60 ± 6 .2
M/F 17/3 18/2
Crossclamp time (min) 55 ± 17 62 ± 14 .1
Bypass time (min) 64 ± 18 75 ± 14 .07
Internal thoracic artery graft 100% 100%
Average grafts per patient 2.7 ± 0.7 3 ± 0.6 .2
Intensive care unit stay (h) 47 ± 35 43 ± 25 .6
Values are means ± SD where shown.
Table II. Preoperative hematologic profile
Placebo 
TA group group P value
Platelets (103) 163 ± 30 160 ± 52 .8
Prothrombin time (s) 12.4 ± 0.9 14.5 ± 1.6 .2
Partial thromboplastin time (s) 29.6 ± 5.2 34.3 ± 14.3 .2
Hemoglobin (g/dL) 12.1 ± 0.8 11.6 ± 1.4 .2
Hematocrit (%) 36 ± 3.5 35.4 ± 4.9 .2
Fibrinogen (mg/dL) 210 ± 84.6 249 ± 54.9 .09
Values shown are means ± SD.
Table III. Postoperative hematologic profile
Placebo 
TA group group P value
Platelets (103) 113 ± 34 113 ± 32 .9
Prothrombin time (s) 17 ± 2.6 16.8 ± 1.5 .8
Partial thromboplastin time (s) 40.8 ± 17 43.2 ± 35 .9
Hemoglobin (g/dL) 9.2 ± 1.5 8.9 ± 1.1 .4
Hematocrit (%) 26.9 ± 3.6 25.6 ± 3 .3
Fibrinogen (mg/dL) 218 ± 71 188 ± 38 .1
Values shown are means ± SD.
monary,22 mesenteric,23 and retinal24 thrombosis have
been described with intravenous administration of TA.
Moreover, two studies have suggested that in CABG
operations the use of aprotinin or TA may be associated
with an increased incidence of early graft occlusion and
postoperative myocardial infarction, although both stud-
ies failed to achieve statistical significance.7,13 Recently,
the International Multicenter Aprotinin Graft Patency
Experience Trial documented that high-dose aprotinin
administered prophylactically to patients with primary
CABG increases the probability of early saphenous vein
graft occlusion.25
In the effort to reduce postoperative bleeding, anti-
fibrinolytic agents have also been applied topically into
the pericardial cavity.26,27 Tatar and colleagues26 first
reported in 1993 that the topical use of aprotinin
reduces postoperative blood loss and the need for trans-
fusion in coronary artery surgery. The fact that apro-
tinin could not be detected in the patients’ blood sug-
gested that its effect was likely due to topical action.
Similar results were described by the Oxford group.27
Thus far, to the best of our knowledge, no prospective,
randomized, double-blind study has been published
concerning the topical use of TA in the pericardial cav-
ity after myocardial revascularization. However, the
hemostatic effect of topical TA in oral surgery,14,15
bladder surgery,12 and gynecologic hemorrhage16 has
been demonstrated. The present study showed that a
single 1-g dose of TA applied into the pericardial cavi-
ty after primary CABG reduces blood loss by 36% dur-
ing the first 3 hours and by 25% during the first 24
hours after operation in comparison with placebo. The
reduction in blood loss occurs principally in the initial
3 postoperative hours. We believe that this may be due
to the early hemostatic effect provided by topical TA. It
has been suggested that a local fibrinolytic state per-
sists after closure of the thoracic cavity and contributes
to the postoperative blood loss.28 The application of TA
into the chest before closure of the median sternotomy
could remove plasminogen from the fibrin surface of
clots, thereby inhibiting plasmin-induced degradation
of fibrin. Thus it might prevent the resolution of formed
clots and lead to hemostasis by preserving their integri-
ty. On the other hand, TA could not be detected in any
of the blood samples collected from the l3 patients of
the treatment group 2 hours after unclamping of the
chest tubes. No studies are currently available regard-
ing the absorption and fate of TA after topical applica-
tion into the pericardial cavity. However, the pharma-
cokinetics of this drug after intravenous, oral, and
intramuscular administration17 allowed us to extrapo-
late that after 2 hours we would expect to detect TA in
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Fig 1. Postoperative blood loss measured every 3 hours.
the plasma if any significant absorption had occurred.
The therapeutic plasma level of TA is approximately 10
to 15 mg/mL. The electron-capture gas chromatogra-
phy has been successfully used for the determination of
levels of TA in plasma as low as 0.2 mg/mL.17 In our
opinion the fact that TA could not be detected in any of
the blood samples collected strongly suggests that the
drug remained restricted to the pericardial space and
that its effect was due to topical action. We appreciate,
however, that a proper pharmacokinetic study needs to
be done to definitely clarify this issue. Our data demon-
strate that the reduction in blood loss in the treatment
group was statistically significant in the initial 3 hours
after operation but not in the following 21 hours. It is
likely that the 1% solution of TA used in this series was
not sufficient to suppress local fibrinolysis for more
than 3 to 4 hours. We believe that a larger dose of TA
(eg, a 5% solution) could prolong the hemostatic effect
of this drug. This hypothesis is in accordance with pre-
viously reported results of treatment in anticoagulant-
treated patients undergoing oral surgery.15
We are aware that in the current study the total reduc-
tion in blood loss in the TA group compared with that
found in the placebo group was less than 200 mL and
therefore relatively small, although statistically signifi-
cant. However, if we define excessive bleeding as total
chest drainage of more than 700 to 800 mL, it should
be stressed that most patients in this series bled little.
Minimal bleeding overall might have helped hide the
hemostatic efficacy of this pharmaceutical agent. Little
postoperative bleeding was the result of both meticu-
lous surgical hemostasis and the relatively low risk for
bleeding of our population. All the patients were
undergoing primary CABG with normothermic CPB,
did not receive platelet-activating drugs within 14 days
of operation, and did not have any kind of bleeding
diathesis. Furthermore, only the left internal thoracic
artery was routinely used as in situ arterial graft. A
greater effect of topical TA in reducing blood loss
could possibly occur in more prolonged and complex
procedures with a higher risk of bleeding.
The failure of the current study to document a reduc-
tion in allogenic transfusions despite a statistically sig-
nificant reduction in blood loss may be related to sev-
eral factors: little overall postoperative bleeding,
stringent transfusion criteria, and sample size insuffi-
cient to demonstrate a modest effect. When surgical
blood loss is already minimal, the beneficial effect of
the drug on consumption of blood products is likely to
be small,29 particularly if transfusion practice follows
stringent guidelines. Indeed, the criteria we adopted
required a hematocrit level of less than 24% to trigger
a transfusion, thus providing an overall low incidence
of transfusions. Because mean postoperative hemat-
ocrit levels exceeded 25% for each group, a group dif-
ference in transfusions would be unexpected. The prac-
tice of transfusion to a higher hematocrit level, such as
a level of less than 30% rather than 24%, could more
easily demonstrate an effect of topical TA on transfu-
sion requirement.
The economic effect on the hospital’s budget of the
topical method described seems to be little. At our
institution, 1000 mg of TA costs $2.50, whereas
1,000,000 kIU of aprotinin, as topically used by Tatar
and colleagues,27 has a price of $62. ε-Aminocaproic
acid has a cost of $0.70 per 1000 mg, but although
there are no data about its topical use, its dosage is
approximately 10 times higher than that of TA when
administered intravenously. The low cost of TA is
attractive, but to be fully justified, a reduction in blood
loss has to be followed by a reduction in the need for
transfusion requirements.
In conclusion, topical application of TA into the peri-
cardial cavity after CPB in patients undergoing CABG
operations significantly reduces postoperative bleeding
in the first 3 hours after operation. This reduction in
blood loss might be the consequence of the potential
local antifibrinolytic effect of TA. When topical TA is
used in a homogeneous population of patients with a
low bleeding risk undergoing primary CABG, the
decrease in blood loss is relatively small. Moreover, no
effect is observed on the prevalence of transfusions,
particularly if heightened attention is given to surgical
hemostasis and stringent transfusion criteria are fol-
lowed. We believe that a more pronounced effect on
both postoperative bleeding and blood product require-
ment might be seen in procedures with a higher bleed-
ing risk (eg, redo operations, complete arterial myocar-
dial revascularization, hypothermic CPB, long CPB
time, preoperative aspirin therapy, or coagulopathy).
Further studies must be carried out to clarify this issue.
Finally, it needs to be established whether a larger dose
of topical TA could prolong the hemostatic action of
this drug.
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